JP2017515881A - 新生児の微生物叢の補充 - Google Patents

新生児の微生物叢の補充 Download PDF

Info

Publication number
JP2017515881A
JP2017515881A JP2016568694A JP2016568694A JP2017515881A JP 2017515881 A JP2017515881 A JP 2017515881A JP 2016568694 A JP2016568694 A JP 2016568694A JP 2016568694 A JP2016568694 A JP 2016568694A JP 2017515881 A JP2017515881 A JP 2017515881A
Authority
JP
Japan
Prior art keywords
probiotic
probiotic microorganism
fetus
oral cavity
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515881A5 (https=
Inventor
モルシュタム、ボー
アーガード、シャースティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Original Assignee
Biogaia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB filed Critical Biogaia AB
Publication of JP2017515881A publication Critical patent/JP2017515881A/ja
Publication of JP2017515881A5 publication Critical patent/JP2017515881A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2016568694A 2014-05-20 2015-05-20 新生児の微生物叢の補充 Pending JP2017515881A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000842P 2014-05-20 2014-05-20
US62/000,842 2014-05-20
PCT/EP2015/061181 WO2015177246A2 (en) 2014-05-20 2015-05-20 Neonatal microbiome supplementation

Publications (2)

Publication Number Publication Date
JP2017515881A true JP2017515881A (ja) 2017-06-15
JP2017515881A5 JP2017515881A5 (https=) 2018-06-14

Family

ID=53284210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568694A Pending JP2017515881A (ja) 2014-05-20 2015-05-20 新生児の微生物叢の補充

Country Status (9)

Country Link
US (1) US20170216375A1 (https=)
EP (1) EP3145520A2 (https=)
JP (1) JP2017515881A (https=)
KR (1) KR20170005806A (https=)
CN (1) CN106879253A (https=)
AU (1) AU2015261869A1 (https=)
CL (1) CL2016002732A1 (https=)
MX (1) MX2016015153A (https=)
WO (1) WO2015177246A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
ES2870425T3 (es) * 2014-10-29 2021-10-27 Biogaia Ab Uso de L. reuteri para la prevención o el tratamiento de la disbiosis de microbiota en la vida temprana
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
CN112236513B (zh) 2018-07-24 2023-09-19 生命大地女神有限公司 选择和使用褪黑素支持细菌以减少婴儿绞痛
CA3103356A1 (en) * 2018-07-24 2020-01-30 Biogaia Ab Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
WO2020028871A1 (en) * 2018-08-03 2020-02-06 Research Institute At Nationwide Children's Hospital Prenatal probiotic formulations
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
EP3870154A4 (en) 2018-10-22 2022-07-27 Research Institute at Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ANTIBIOTIC-INDUCED PATHOLOGIES USING PROBIOTICS IN BIOFILM STATE
EP3979830B1 (en) 2019-06-03 2025-11-26 Research Institute at Nationwide Children's Hospital Formulations for the treatment of neurodevelopmental deficiencies induced by necrotizing enterocolitis
CA3238788A1 (en) 2021-11-22 2023-05-25 Eric Michael Schott Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
WO2023201092A1 (en) * 2022-04-14 2023-10-19 Washington University Prevotella copri formulations and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098032A1 (en) * 2011-12-30 2013-07-04 Nestec S.A. Lactobacillus reuteri dsm 17938 for the development of the enteric nervous system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
EP2147678A1 (en) * 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
EP2295535A1 (en) * 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013098032A1 (en) * 2011-12-30 2013-07-04 Nestec S.A. Lactobacillus reuteri dsm 17938 for the development of the enteric nervous system

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. PEDIATR., vol. 162, JPN6019008106, 2013, pages 257 - 262, ISSN: 0004165883 *
JAMA PEDIATR., vol. 168, no. 3, JPN6019008110, January 2014 (2014-01-01), pages 228 - 233, ISSN: 0004165885 *
NEONATOLOGY, vol. 102, JPN6019008103, 2012, pages 178 - 184, ISSN: 0004165882 *
PEDIATRICS, vol. 126, JPN6019008108, 2010, pages 526 - 533, ISSN: 0004165884 *
PEDIATRICS, vol. 132, JPN6019008102, 2013, pages 666 - 676, ISSN: 0004165881 *

Also Published As

Publication number Publication date
WO2015177246A2 (en) 2015-11-26
US20170216375A1 (en) 2017-08-03
KR20170005806A (ko) 2017-01-16
EP3145520A2 (en) 2017-03-29
WO2015177246A3 (en) 2016-03-03
MX2016015153A (es) 2017-03-07
WO2015177246A8 (en) 2016-01-14
CN106879253A (zh) 2017-06-20
CL2016002732A1 (es) 2017-04-28
AU2015261869A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
JP2017515881A (ja) 新生児の微生物叢の補充
Taylor et al. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial
US20250017988A1 (en) Probiotic Delivery Systems
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
MX2012011270A (es) Pienso para acondicionar la flora intestinal de terneras.
US11274275B2 (en) Lactobacillus paracasei ET-22 and use thereof
JP2010265303A (ja) 下痢の処置方法
Adamek et al. Prenatal and early childhood development of gut microbiota.
CN115068591B (zh) 一种包含骨桥蛋白的益生菌组合物
JP6837442B2 (ja) 乳酸菌を活性化する方法
Juhl Necrotizing enterocolitis-classification and two initial steps towards prevention
JP2023550962A (ja) アトピー性疾患を予防、遅延、又は改善する方法
Herman et al. Prevention of IgE-mediated food allergy: emerging strategies through maternal and neonatal interventions
Ripoll et al. scFOS supplemented follow-on formula in healthy infants: impact on vaccine specific faecal secretory IGA response, faecal bifidobacteria, growth and digestive tolerance
JP2022504185A (ja) 細菌株を含む組成物
Yamashiro et al. Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy
CN116391026A (zh) 产生丝氨酸蛋白酶抑制剂
CN109310718B (zh) 上消化道内菌群改善剂
RU2203076C1 (ru) Способ лечения и профилактики желудочно-кишечных болезней телят
HK40081564A (zh) 一种包含骨桥蛋白的益生菌组合物
HK40081564B (en) A probiotic combination containing osteopontin
HK40099244A (zh) 预防、延迟或改善特应性疾病的方法
WO2025132375A1 (en) Lactobacillus paracasei and combination of microorganisms with lactobacillus paracasei
JP2025520134A (ja) 小児アトピー性疾患を治療又は予防するための組み合わせ方法
SOFTIĆ et al. Antimicrobial resistance by bacteria that colonize neonates with suspected sepsis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191203